# Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

> **NCT04354402** · — · COMPLETED · sponsor: **SymBio Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT04354402
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-26
- **Primary completion:** 2020-11-11
- **Final completion:** 2020-11-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04354402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04354402, "Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04354402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*